Tirzepatide (60mg)

Intelligent metabolic regulation for consistent weight loss.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability).
It acts on appetite/satiety centres, helping to reduce food intake and supporting adherence to body recomposition strategies.

Key Benefits

  • Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
  • Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
  • Cardiometabolic improvements associated with weight loss and incretin pathway activity.
  • Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).

SKU:

Tags:

Intelligent metabolic regulation for consistent weight loss.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability).
It acts on appetite/satiety centres, helping to reduce food intake and supporting adherence to body recomposition strategies.

Key Benefits

  • Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
  • Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
  • Cardiometabolic improvements associated with weight loss and incretin pathway activity.
  • Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).

Technical Details

Part Number

Item Weight

Product Dimensions

Item model number

Item Package Quantity

Number of Handles

Batteries Required?

product without indications
SURMOUNT-1 (NEJM, 2022 | Phase 3): Over 72 weeks, mean weight loss of −15.0%, −19.5%, and −20.9% (5/10/15 mg), with cardiometabolic benefits and gastrointestinal events predominantly mild to moderate.
product without recommended dosages

Related Products

SS-31 (10 X 50mg Vial)

SS-31 50 mg (Elamipretide)

Cellular energy and mitochondrial health support.

SS-31 is a peptide developed to act on mitochondria, the structures responsible for cellular energy production. By supporting mitochondrial function, it may contribute to improved physical performance, muscle recovery, endurance, and support for healthy aging.

Who is it for?

SS-31 may be an option for individuals who seek to:

• Improve energy levels and overall vitality.
• Support recovery after intense training.
• Promote muscle and cardiovascular health.
• Encourage healthy aging with a focus on cellular function.
• Maintain high physical and cognitive performance.

What are the main benefits?

• Supports efficient cellular energy production.
• Helps reduce oxidative stress at the cellular level.
• Promotes muscle recovery and physical endurance.
• Supports mitochondrial health, essential for overall body function.
• May contribute to greater vitality and day-to-day performance.

How to use?

The usage protocol should be defined by a physician or qualified professional, according to individual goals and needs.

CJC-1295 (NO DAC) (5 mg) + Ipamorelin (5 mg) (10 X 10mg Vial)

A synergistic combination developed to stimulate the body’s natural release of growth hormone (GH) in a physiology-aligned way. By acting through two complementary pathways, it supports more consistent GH pulses and IGF-1 support, helping to sustain performance, recovery, and body composition.

Key Benefits

Stimulates the body’s own GH: helps the body release growth hormone in a pattern closer to natural physiology (in “pulses”).

Supports recovery and repair: may aid recovery (sleep, post-training, regeneration) by reinforcing GH/IGF-1–related signalling.

Body composition support: associated with a better balance between lean mass and fat, supporting body recomposition.

More efficient metabolism: may promote energy utilisation and support fat and protein metabolism.

Vitality and performance: many people seek a greater sense of energy and a steadier performance rhythm throughout the protocol.

Tesamorelin (10 X 10mg Vial)

Less visceral fat, more definition.
Tesamorelin is a synthetic 44–amino acid peptide, an analogue of GHRH, with an N-terminal modification for improved stability. In studies, it acts on GHRH receptors in the anterior pituitary, stimulating endogenous release of growth hormone (GH) and increasing IGF-1 systemically and also locally in various tissues, with effects investigated in metabolism and body composition.

Key Benefits

  • Advanced support for reducing visceral fat
  • Optimisation of body recomposition
  • Improved metabolic efficiency and energy levels
  • Support for tissue recovery and physiological performance
  • Strong alignment with healthy ageing strategies

MOTS-C (10 X 40 mg Vial)

MOTS-c is a peptide produced by the mitochondrion (the cell’s “energy plant”). It is being studied for helping the body use energy more efficiently, by stimulating a pathway similar to the one activated by exercise and by metformin. As a result, it may support the use of fat for energy and improve the way muscles take up sugar (glucose).

Key Benefits

Insulin sensitivity: significantly improves how the body processes sugar, helping to counter insulin resistance.

Weight management: supports fat oxidation and may help prevent weight gain caused by high-fat diets.

Physical performance: increases endurance capacity and mitochondrial biogenesis (the creation of new cellular “power plants”).

Longevity and anti-ageing: its replenishment is associated with protection against degenerative diseases.

Bone health: studies suggest it may help prevent osteoporosis by promoting osteoblast differentiation.